ACRS ▼ -6.0% - Aclaris Therapeutics, Inc. $ACRS - Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) 16-NOV-2026 03:28 AM ET